Highlight
This article summarizes results from two large-scale, phase 3 clinical trials, REMODEL-1 and REMODEL-2, that compared remibrutinib, a potent oral Bruton’s tyrosine kinase (BTK) inhibitor, to teriflunomide in adult patients with relapsing multiple sclerosis (MS). Both trials demonstrated that remibrutinib significantly reduced annual relapse rates compared to teriflunomide, while maintaining a favorable safety profile and fewer adverse events leading to treatment discontinuation.
